What is the price target for BBOT stock?
15 analysts have analysed BBOT and the average price target is 24.48 USD. This implies a price increase of 158.23% is expected in the next year compared to the current price of 9.48.
BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) Forecast, Price Target & Analyst Ratings
NASDAQ:BBOT • US1079241022
Current stock price
9.48 USD
+0.38 (+4.12%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for BRIDGEBIO ONCOLOGY THERAPEUT (BBOT).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 7, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.53
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$24.48
Upside
+ 158.23%
From current price of $9.48 to mean target of $24.48, Based on 15 analyst forecasts
Low
$18.18
Median
$23.97
High
$33.60
Price Target Revisions
1 Month
-0.59%
3 Months
0.00%
Price Target Summary
15 Wall Street analysts provided a forecast for the next 12 months for BBOT. The average price target is 24.48 USD. This implies a price increase of 158.23% is expected in the next year compared to the current price of 9.48.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
86.67%
BBOT was analyzed by 15 analysts. The buy percentage consensus is at 87. So analysts seem to be very confident about BBOT.
In the previous month the buy percentage consensus was at a similar level.
BBOT was analyzed by 15 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-06 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-02-11 | Stifel | Initiate | Buy |
| 2026-01-09 | Raymond James | Initiate | Outperform |
| 2025-12-11 | Wedbush | Reiterate | Outperform -> Outperform |
| 2025-12-05 | Morgan Stanley | Initiate | Overweight |
| 2025-11-25 | Wedbush | Reiterate | Outperform -> Outperform |
| 2025-11-13 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-09-17 | Leerink Partners | Initiate | Outperform |
| 2025-09-15 | HC Wainwright & Co. | Initiate | Buy |
| 2025-09-04 | Oppenheimer | Initiate | Outperform |
| 2025-08-18 | Wedbush | Initiate | Outperform |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 7, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.53
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- N/A
- Number of Analysts
- 11
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
BBOT is expected to report earnings on 5/7/2026. The consensus EPS estimate for the next earnings is -0.53 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | |||||
| EBITDA YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A -62.81% | N/A -11.48% | |
| EBIT YoY % growth | -43.4K | -3.5K 91.94% | -41.7K -1,091.43% | -584.4K -1,301.44% | N/A -25,202.48% | N/A -44.76% | N/A -18.83% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A 29.64% | N/A -14.37% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.53 | -0.57 | -0.61 41.01% | -0.61 -24.27% | -0.56 -4.91% | -0.52 8.68% | -0.54 11.86% | -0.55 10.22% |
| Revenue Q2Q % growth | ||||||||
| EBITDA Q2Q % growth | -45.324M | -54.376M | -56.508M | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -46.25M -1,810.20% | -49.27M -4,291.70% | -51.637M -64.77% | -52.822M -8.37% | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-111.94%
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
-650.81%
EBIT Next 5 Year
N/A
BRIDGEBIO ONCOLOGY THERAPEUT / BBOT Forecast FAQ
When does BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) report earnings?
BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) will report earnings on 2026-05-07.
What are the consensus estimates for BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) next earnings?
The consensus EPS estimate for the next earnings of BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) is -0.53 USD and the consensus revenue estimate is 0 USD.
How many analysts cover BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) stock?
The number of analysts covering BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) is 15.